Phase 1 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older of any sex who have at least one psoriasis skin plaque larger than 5 cm² (roughly the size of a large postage stamp), with a psoriasis diagnosis made at least one year before joining, where the condition ranges from mild (faint thickening, light pink colour, fine flaking) to moderate (more noticeable thickening, brighter red colour, moderate flaking).
• People who have previously received treatment for psoriasis, or who have never been treated for it.
• Women who could become pregnant must agree to use effective birth control (such as abstinence, an intrauterine device, or a double-barrier method) throughout the study and for at least 3 months after it ends.
• People who are mentally able to understand what the study involves and are willing to sign a consent form.
• People who are able to attend the required study visits and complete the investigations outlined in the study plan.

Who may not be able to join:

• People whose psoriasis is not the chronic plaque type — for example, those with drug-triggered, guttate, erythrodermic, or pustular forms of psoriasis.
• People who have had a significant worsening (flare) of their psoriasis in the 12 weeks before the study start date, as determined by the study investigators.
• People who have another inflammatory skin condition (such as eczema/atopic dermatitis) or a skin infection (such as cellulitis, warts, or fungal skin infections).
• People currently using, or who have recently used, certain psoriasis medications that could affect how the study results are measured, unless enough time has passed since stopping them (the trial site can advise on specific medications and waiting periods).
• People with a known serious heart condition, such as heart failure with symptoms, unstable chest pain, a heart attack in the past 6 months, uncontrolled heart rhythm problems, or a heart condition classified as stage III or IV by standard medical guidelines.
• People with known risk factors for a specific serious heart rhythm problem called torsade de pointes — for example, significant heart failure, low potassium levels, or a family history of Long QT Syndrome.
• People who have had a blood clot in an artery, a stroke, or a mini-stroke (transient ischaemic attack) in the past 12 months.
• People with uncontrolled high blood pressure (readings above 160/90 mmHg) or significant disease of the blood vessels in the limbs.
• People with known active tumours or cancer spread involving the brain or spinal area.
• People with any active uncontrolled bleeding, conditions that cause a tendency to bleed (such as active stomach ulcers), or a history of significant bleeding (such as coughing up blood or gastrointestinal bleeding) in the past 6 months.
• People who become seriously short of breath with light to moderate activity, have large or recurring fluid build-ups around the lungs or abdomen requiring frequent draining, or have any clinically significant fluid around the heart.
• People with any type of diabetes, except for well-controlled type 2 diabetes (non-insulin dependent) with a blood sugar control reading (HbA1c) of 8% or below (confirm with trial site).
• People who have an active infection at the time of screening, or who have had a serious infection in the past month.
• People known to have HIV, hepatitis B, hepatitis C, or active or latent tuberculosis.
• People with a serious or poorly healing wound, skin ulcer, or bone fracture.
• People who have had an abdominal fistula, a hole in the gastrointestinal tract, or an abdominal abscess in the past 6 months.
• People with significant nerve damage (neuropathy graded 2 or higher) (confirm with trial site).
• People who are pregnant or currently breastfeeding.
• People who plan to deliberately expose the skin areas being studied to sunlight during the trial.

Important: Always verify eligibility with the trial site directly before applying.